Log in
Enquire now
‌

US Patent 9631026 Antibodies that specifically bind to TIM3

Patent 9631026 was granted and assigned to Cellerant Therapeutics on April, 2017 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Patent abstractTimelineTable: Further ResourcesReferences
Is a
Patent
Patent
1

Patent attributes

Patent Applicant
Cellerant Therapeutics
Cellerant Therapeutics
1
Current Assignee
Cellerant Therapeutics
Cellerant Therapeutics
1
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
1
Patent Number
96310261
Patent Inventor Names
Ying-Ping Jiang1
Holger Karsunky1
Date of Patent
April 25, 2017
1
Patent Application Number
144580531
Date Filed
August 12, 2014
1
Patent Citations Received
‌
US Patent 11712468 CD70 combination therapy
2
Patent Primary Examiner
‌
Brad Duffy
1
Patent abstract

Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9631026 Antibodies that specifically bind to TIM3

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.